Augmentin (amoxycillin and clavulanic acid) in the treatment of urinary tract infections.
Augmentin (amoxycillin and clavulanic acid) is a new oral antibiotic combination which is particularly indicated in the treatment of urinary tract infections. Potentiation of amoxycillin by the clavulanic acid reduces the level of resistance in most Gram-negative urinary pathogens and these organisms are then sensitive to urinary levels of amoxycillin achieved on standard dosage. Clinical trials in urinary tract infections have shown a success rate of about 70 per cent for amoxycillin-resistant organisms. Augmentin in a dose of 375 mg tds is well tolerated and minimal gastrointestinal side effects occur. Augmentin is a novel antibiotic combination and will be particularly valuable in the oral treatment of urinary tract infections caused by multiply resistant bacteria.
D000658:Amoxicillin / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D004338:Drug Combinations / Q000627:therapeutic use; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D010403:Penicillin Resistance; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D001618:beta-Lactamases / Q000378:metabolism
D004338:Drug Combinations; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D001618:beta-Lactamases